Magnus Jonsbu

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND The use of sulphonylureas for type 2 diabetes has been debated since 1970, when the University Group Diabetes Program (UGDP) reported increased cardiovascular mortality with tolbutamide treatment. MATERIAL AND METHODS We try to present a balanced review of the current knowledge of the possible cardiovascular side effects of sulphonylureas. (More)
  • 1